Clinical practice guidelines for the management of adult diffuse gliomas
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical practice guidelines for the management of adult diffuse gliomas
Authors
Keywords
Molecular diagnostics, Surgery, Chemoradiation, Immune therapy, Target therapy
Journal
CANCER LETTERS
Volume 499, Issue -, Pages 60-72
Publisher
Elsevier BV
Online
2020-11-06
DOI
10.1016/j.canlet.2020.10.050
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
- (2020) Daniel J. Brat et al. ACTA NEUROPATHOLOGICA
- Spatiotemporal dynamics of postoperative functional plasticity in patients with brain tumors in language areas
- (2020) Mikel Lizarazu et al. BRAIN AND LANGUAGE
- Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
- (2020) David A. Reardon et al. CLINICAL CANCER RESEARCH
- Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers
- (2020) Vivek Subbiah et al. Cancer Discovery
- Association of Maximal Extent of Resection of Contrast-Enhanced and Non–Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma
- (2020) Annette M. Molinaro et al. JAMA Oncology
- cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading
- (2020) David N. Louis et al. BRAIN PATHOLOGY
- Motor Cortical Network Plasticity in Patients With Recurrent Brain Tumors
- (2020) Lucia Bulubas et al. Frontiers in Human Neuroscience
- Awake craniotomy for gliomas involving motor-related areas: classification and function recovery
- (2020) Shengyu Fang et al. JOURNAL OF NEURO-ONCOLOGY
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
- (2020) David A. Reardon et al. JAMA Oncology
- Management of glioblastoma: State of the art and future directions
- (2020) Aaron C. Tan et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
- (2020) Ingo K. Mellinghoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions
- (2020) Anna Luisa Di Stefano et al. NEURO-ONCOLOGY
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
- (2019) Timothy F. Cloughesy et al. NATURE MEDICINE
- Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
- (2019) Kurt A. Schalper et al. NATURE MEDICINE
- cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation
- (2019) David W. Ellison et al. ACTA NEUROPATHOLOGICA
- Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2019) Anoop P Patel et al. LANCET NEUROLOGY
- PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas
- (2019) R Appay et al. NEURO-ONCOLOGY
- Novel IDH1-Targeted Glioma Therapies
- (2019) Georg Karpel-Massler et al. CNS DRUGS
- ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)
- (2019) Andrew Lassman et al. NEURO-ONCOLOGY
- INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFRamplified glioblastoma
- (2019) Martin van den Bent et al. NEURO-ONCOLOGY
- A Novel Sequence: ZOOMit-Blood Oxygen Level-Dependent for Motor-Cortex Localization
- (2019) Shengyu Fang et al. NEUROSURGERY
- cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant
- (2018) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Novel, improved grading system(s) for IDH-mutant astrocytic gliomas
- (2018) Mitsuaki Shirahata et al. ACTA NEUROPATHOLOGICA
- cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC)
- (2018) David N. Louis et al. ACTA NEUROPATHOLOGICA
- A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis
- (2018) Shunichi Koriyama et al. Brain Tumor Pathology
- Machine Learning-Based Radiomics for Molecular Subtyping of Gliomas
- (2018) Chia-Feng Lu et al. CLINICAL CANCER RESEARCH
- Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI
- (2018) Yu Fujii et al. JOURNAL OF NEUROSURGERY
- CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
- (2018) Stephen J Bagley et al. NEURO-ONCOLOGY
- The clinicopathological and prognostic significance of TP53 alteration in K27M mutated gliomas: an individual-participant data meta-analysis
- (2018) Chengya Dong et al. NEUROLOGICAL SCIENCES
- Recurrent Glioblastoma Treated with Recombinant Poliovirus
- (2018) Annick Desjardins et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide
- (2018) Erica H. Bell et al. JAMA Oncology
- Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma
- (2018) Damian Stichel et al. ACTA NEUROPATHOLOGICA
- cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”
- (2018) Daniel J. Brat et al. ACTA NEUROPATHOLOGICA
- The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study
- (2018) Xiaojie Ding et al. JOURNAL OF NEURO-ONCOLOGY
- Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor
- (2018) Huimin Hu et al. CELL
- Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2018) Giuseppe Lombardi et al. LANCET ONCOLOGY
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
- (2017) Roger Stupp et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Response Assessment in Neuro-Oncology Clinical Trials
- (2017) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma
- (2017) Ryan S. Youland et al. JOURNAL OF NEURO-ONCOLOGY
- Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
- (2017) Martin J van den Bent et al. LANCET
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- (2017) Michael Weller et al. LANCET ONCOLOGY
- European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
- (2017) Michael Weller et al. LANCET ONCOLOGY
- European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma
- (2017) Andrea Pace et al. LANCET ONCOLOGY
- EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
- (2017) Faizaan Mohammad et al. NATURE MEDICINE
- Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
- (2017) Andrea Piunti et al. NATURE MEDICINE
- Prognostic relevance of genetic alterations in diffuse lower-grade gliomas
- (2017) Kosuke Aoki et al. NEURO-ONCOLOGY
- A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
- (2017) Prakash Chinnaiyan et al. NEURO-ONCOLOGY
- The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis
- (2017) Maarten M J Wijnenga et al. NEURO-ONCOLOGY
- Supratotal resection of diffuse gliomas – an overview of its multifaceted implications
- (2017) Y.N. Yordanova et al. NEUROCHIRURGIE
- The Role of Extent of Resection in IDH1 Wild-Type or Mutant Low-Grade Gliomas
- (2017) Toral Patel et al. NEUROSURGERY
- Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
- (2017) James R. Perry et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours
- (2017) Farhana Haque et al. Acta Neuropathologica Communications
- The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
- (2017) Yujin Lee et al. Acta Neuropathologica Communications
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Statistical Report of Central Nervous System Tumors Histologically Diagnosed in the Sichuan Province of China from 2008 to 2013: A West China Glioma Center Report
- (2016) Xiang Wang et al. ANNALS OF SURGICAL ONCOLOGY
- Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel
- (2016) Angela Zacher et al. BRAIN PATHOLOGY
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- CGCG clinical practice guidelines for the management of adult diffuse gliomas
- (2016) Tao Jiang et al. CANCER LETTERS
- Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
- (2016) W. Wick et al. CLINICAL CANCER RESEARCH
- Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
- (2016) Jayashree Kalpathy-Cramer et al. JOURNAL OF NEURO-ONCOLOGY
- Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion
- (2016) Tomohiro Kawaguchi et al. JOURNAL OF NEURO-ONCOLOGY
- Clonal evolution of glioblastoma under therapy
- (2016) Jiguang Wang et al. NATURE GENETICS
- Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
- (2016) NATURE MEDICINE
- Classification based on mutations ofTERTpromoter andIDHcharacterizes subtypes in grade II/III gliomas
- (2016) Pei Yang et al. NEURO-ONCOLOGY
- Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma
- (2016) Lee A. Wheeler et al. NEURO-ONCOLOGY
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Post-Surgical Language Reorganization Occurs in Tumors of the Dominant and Non-Dominant Hemisphere
- (2016) M. Avramescu-Murphy et al. Clinical Neuroradiology
- Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
- (2016) Zheng Wang et al. OncoImmunology
- Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up
- (2015) Hugues Duffau ACTA NEUROCHIRURGICA
- Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups
- (2015) Michael Weller et al. ACTA NEUROPATHOLOGICA
- Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma
- (2015) A. L. Di Stefano et al. CLINICAL CANCER RESEARCH
- Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424
- (2015) Barbara J. Fisher et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
- (2015) Hideho Okada et al. LANCET ONCOLOGY
- Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
- (2015) Jeanette E. Eckel-Passow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma
- (2014) Benedikt Wiestler et al. ACTA NEUROPATHOLOGICA
- RNA-seq of 272 gliomas revealed a novel, recurrentPTPRZ1-METfusion transcript in secondary glioblastomas
- (2014) Zhao-Shi Bao et al. GENOME RESEARCH
- Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma
- (2014) L. Chen et al. NEURO-ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China
- (2013) Chuan-Bao Zhang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution
- (2013) Pei Yang et al. JOURNAL OF NEURO-ONCOLOGY
- The integrated landscape of driver genomic alterations in glioblastoma
- (2013) Veronique Frattini et al. NATURE GENETICS
- Updated Therapeutic Strategy for Adult Low-Grade Glioma Stratified by Resection and Tumor Subtype
- (2013) Masayuki NITTA et al. NEUROLOGIA MEDICO-CHIRURGICA
- Supratentorial Gliomas in Eloquent Areas: Which Parameters Can Predict Functional Outcome and Extent of Resection?
- (2013) Giannantonio Spena et al. PLoS One
- TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
- (2013) P. J. Killela et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma
- (2012) Dominik Sturm et al. CANCER CELL
- Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
- (2012) Gregory Cairncross et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
- (2012) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- (2012) Sevin Turcan et al. NATURE
- Thromboembolic disease in patients with high-grade glioma
- (2012) J. R. Perry NEURO-ONCOLOGY
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- An extent of resection threshold for newly diagnosed glioblastomas
- (2011) Nader Sanai et al. JOURNAL OF NEUROSURGERY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures
- (2010) Justin B. Usery et al. JOURNAL OF NEURO-ONCOLOGY
- Surgical treatment of high-grade gliomas in motor areas. The impact of different supportive technologies: a 171-patient series
- (2010) Andrea Talacchi et al. JOURNAL OF NEURO-ONCOLOGY
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)
- (2010) F. M. Iwamoto et al. NEURO-ONCOLOGY
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
- (2010) J. H. Sampson et al. NEURO-ONCOLOGY
- All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
- (2010) M. Labussiere et al. NEUROLOGY
- Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
- (2009) Jennifer L. Clarke et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of anti-epileptic drugs in patients with gliomas and seizures
- (2009) Mèlanie S. M. Breemen et al. JOURNAL OF NEUROLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Independent association of extent of resection with survival in patients with malignant brain astrocytoma
- (2008) Matthew J. McGirt et al. JOURNAL OF NEUROSURGERY
- Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
- (2008) Dieta Brandsma et al. LANCET ONCOLOGY
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now